Concepedia

Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis

Daniel J. Huynh, Benjamin D. Renelus, Daniel S. Jamorabo

BMC Gastroenterology · 2023 · 18 citations · 21 references

DOIFull text

Open access

References

21

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Vlado Perkovic, Meg Jardine, Bruce Neal et al. · New England Journal of Medicine · 2019 · 5.7K citations · Full text

Liver cirrhosis

The Lancet · 2021 · 1.4K citations

Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis

Narjes Nasiri‐Ansari, Chrysa Nikolopoulou, Katerina Papoutsi et al. · International Journal of Molecular Sciences · 2021 · 278 citations · Full text

Prognostic indicators of survival in patients with compensated and decompensated cirrhosis

Alexander Zipprich, Guadalupe García–Tsao, Sebastian Rogowski et al. · Liver International · 2012 · 276 citations

Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake

Kosuke Kaji, Norihisa Nishimura, Kenichiro Seki et al. · International Journal of Cancer · 2017 · 242 citations